AZN Astrazeneca 6-K2021Farxiga Granted Priority Review In the Us for the Treatment of Patients with Chronic Kidney Disease
6 Jan 21
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
AZN 6-K Filings
- 20 Jan 21 Enhertu Approved In the Eu for Breast Cancer
- 19 Jan 21 Enhertu Approved In the Us for Gastric Cancer
- 15 Jan 21 Imfinzi Approved In the Eu for Less-frequent, Fixed- Dose Use In Unresectable Non-small Cell Lung Cancer
- 6 Jan 21 Farxiga Granted Priority Review In the Us for the Treatment of Patients with Chronic Kidney Disease
- 4 Jan 21 Total Voting Rights
- 4 Jan 21 Atacand Divestment to Cheplapharm In More Than 70 Countries Completed
- 30 Dec 20 Astrazeneca's COVID-19 Vaccine Authorised In Uk
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…